Axonics receives regulatory approval for rechargeable SNM System in Australia

Axonics announced that it has received regulatory approval from the Therapeutic Goods Administration for marketing the Axonics R20 rechargeable sacral neuromodulation system in Australia to treat adults with overactive bladder and fecal incontinence. The R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once every 6 to 10 months for only one hour. The implant utilizes the same small 5cc form factor as the previous generation and is paired with the same tined lead and intuitive, easy to use patient remote control. The R20 also provides physicians and their patients with enhanced programming capabilities and expanded MRI labeling. Axonics expects to commence sales of the R20 to Australian customers in November.